title: Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases.
abstract: OBJECTIVE
  We previously showed that pre-treatment serum anti-E1E2 predicted hepatitis C virus (HCV) RNA viral kinetics (VKs) and treatment outcome in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (Peg-IFN/RBV) double therapy. Here, we determined whether baseline anti-E1E2 was correlated with the on-treatment VK and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving protease inhibitor-based triple therapy.
  
  
  METHODS
  Sera from 19 patients with HCV genotype 1 infection and compensated cirrhosis who failed to respond to a prior course of Peg-IFN/RBV were selected at time 0 before starting triple therapy with boceprevir or telaprevir. We assessed patients with sustained viral response 12 weeks after the end of triple therapy (SVR12) by analyzing VKs at weeks 4, 12, 24, 36, 48 (end of treatment) and 60.
  
  
  RESULTS
  Patients baseline characteristics were similar to the well-defined CUPIC cohort (age, HCV subtype, baseline viremia, and treatment history). Among the 19 patients, 11 achieved an SVR12. Fifteen patients were positive for pre-treatment anti-E1E2 and all of them achieved SVR12. Moreover, anti-E1E2 and SVR12 correlated with prior response to IFN/RBV therapy (relapse, partial or null response).
  
  
  CONCLUSIONS
  Baseline anti-E1E2 could be considered as a new biomarker to predict SVR12 after triple therapy in this most difficult-to-treat population. These results warrant further validation on larger cohorts including patients receiving highly effective direct-acting antivirals to explore whether this test could help in better defining treatment duration for these very costly molecules.
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France. Electronic address: marie-anne.petit@inserm.fr.
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Petit
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France.
authors.forename: Pascale
authors.initials: P
authors.lastname: Berthillon
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France; Hospices civils de Lyon, hôpital de la Croix-Rousse, service d'hépatologie et de gastroentérologie, 69004 Lyon, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Pradat
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France.
authors.forename: Clémence
authors.initials: C
authors.lastname: Arnaud
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bordes
authors.affiliation: Hospices civils de Lyon, hôpital de la Croix-Rousse, service d'hépatologie et de gastroentérologie, 69004 Lyon, France; École normale supérieure, 69007 Lyon, France.
authors.forename: Victor
authors.initials: V
authors.lastname: Virlogeux
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France; Hospices civils de Lyon, hôpital de la Croix-Rousse, service d'hépatologie et de gastroentérologie, 69004 Lyon, France.
authors.forename: Marianne
authors.initials: M
authors.lastname: Maynard
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France; Hospices civils de Lyon, hôpital de la Croix-Rousse, service d'hépatologie et de gastroentérologie, 69004 Lyon, France.
authors.forename: François
authors.initials: F
authors.lastname: Bailly
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France; Hospices civils de Lyon, hôpital de la Croix-Rousse, service d'hépatologie et de gastroentérologie, 69004 Lyon, France.
authors.forename: Fabien
authors.initials: F
authors.lastname: Zoulim
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Chemin
authors.affiliation: Centre de recherche en cancérologie de Lyon (CRCL), UMR I 1052/CNRS 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard Lyon 1, 69100 Villeurbanne, France; Hospices civils de Lyon, hôpital de la Croix-Rousse, service d'hépatologie et de gastroentérologie, 69004 Lyon, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Trépo
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000276:immunology*; D010865:Pilot Projects; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D000998:Antiviral Agents; C116123:E1E2 peptide; D010455:Peptides